Artificial Intelligence
Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics
New collaboration mitigates risk in drug discovery process with artificial intelligence and in vitro “avatar” clinical trials
CHERRY HILL, N.J., April 22, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant” or the “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery techniques, announces a collaboration that will seek to de-risk the development of small protein therapeutics. In partnership with Ordaōs Bio (“Ordaōs”) and Cellaria, Inc. (“Cellaria”), the Company is unveiling a model for rapid iteration of therapeutic design using artificial intelligence and in vitro ‘avatar clinical trials’ that will enable the design, development, and testing of potential therapeutics on specific patient populations, during preclinical development. The goal is to provide an early detection system of a drug’s efficacy in different patient cohorts, prior to clinical trials.
The collaboration capitalizes on the unique capabilities of each company to design, manufacture, and test small-protein therapeutics that target multiple biomarkers derived from whole genome sequencing of patient populations. Using proprietary AI, Ordaōs will generate in silico protein sequences, designed to bind specific disease targets, and will serve as a blueprint for the collaborative team’s experts in in vitro and in vivo preclinical drug discovery, to produce the protein and rapidly iterate the structure using a highly efficient expression system. Using Cellaria’s Patient Specific Cell Model Cohorts, the purified protein will be critically evaluated for target binding and further optimized to improve performance across an array of disease-specific genetic biomarker expressing cells. Once fully optimized by the team, Vyant Bio’s objective will be to deliver regulatory readiness and a maximally de-risked drug candidate. The combined solution will provide data and human-based insights not usually available until after a costly clinical trial.
“Vyant Bio is committed to transforming the way that drugs are discovered by quickly adapting to exciting new technologies and combining capabilities in ways that leverage their strengths,” stated Jay Roberts, CEO of Vyant Bio. “Our collaboration with Ordaōs and Cellaria allows us all to work together to design and develop superior therapeutics and position them to be as successful as possible before they get into the clinic.”
Cellaria Inc. uses cell biology in novel ways to provide insights into how a therapeutic may perform in specific patient populations, prior to clinical trials. In this collaboration, Cellaria provides the means for scientists to test how a drug will perform in a range of patient cohorts. The Cellaria in vitro and 3-D Models of tumor and metastatic niches are directly linked to a patient’s disease state and enable multiple parametric deep data sets in genomics, proteomics, and combinatorial analysis.
“Working with the Ordaōs and Vyant Bio teams has been incredibly important for us. Seeing the wealth of patient data and cells used so seamlessly to inform and guide the design of a therapeutic is highly rewarding,” stated David Deems, President and Founder of Cellaria Inc. “We are developing a repeatable process that leverages well defined patient cohorts to learn as much as possible prior to embarking on a clinical trial.”
Ordaōs uses generative AI technology to accelerate the mini protein drug discovery and development process. In this collaboration, Ordaōs provides a pipeline of digitally optimized therapeutics for further development. The company was founded by David Longo, a Stanford and Harvard-trained AI and biotech scientist, and Ulo Palm, MD, PhD, a 30-year veteran of clinical drug discovery and development at Allergan, Novartis, and Schering Plough.
“We are very excited about working with Vyant Bio and Cellaria to further our vision for transforming the way we bring therapeutics to patients. At Ordaōs, we believe that designing, rather than discovering, drugs is now possible with AI and will allow us to think bigger when we envision the impact we can have on people’s lives.” said David Longo, CEO of Ordaōs.
Ülo Palm, Ordaōs’ Chief Medical Officer, added that “the ultimate goal is to use modern AI to design the next generation of highly effective and safe biologics for treating cancer and inflammatory diseases thereby creating transformative treatment options for potentially millions of patients worldwide. We expect that this new approach will significantly accelerate drug R&D overall and get the new drugs to patients much faster than with the traditional drug development approach. Patients who suffer from chronic and life-threatening diseases cannot wait. That is why this new collaboration is so important.”
The three companies will continue to refine their strategies for drug design and development through a series of projects targeting cancer, pancreatic, and autoimmune disorders. As the project evolves, the therapeutic de-risking strategy will further incorporate the human-based biology and analytical software of StemoniX, a wholly owned subsidiary of Vyant Bio.
About Vyant Bio, Inc.
Vyant Bio, Inc. (“Vyant Bio”) is emerging as an advanced biotechnology drug discovery company. With capabilities in data, science (both biology and chemistry), engineering, and regulatory, we are rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. Leveraging these modalities, Vyant Bio is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm and is empowering the discovery of new medicines through the convergence of novel human biology and software technologies.
StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to conduct research quickly and economically with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients.
vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries, and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.
About Ordaōs Bio
Ordaōs employs a powerful proprietary AI engine and biological expertise to allow researchers to see critical patterns and relationships in their data, unlocking previously unattainable and actionable insights to design—rather than discover—novel therapeutic molecules. This will enable Ordaōs to accelerate medical research, design complex therapeutic candidates and predict the outcomes of clinical trials.
About Cellaria , Inc.
Cellaria identifies disruptive ways to develop new in vitro and 3-D Models of tumors and metastatic niches that are more directly linked to the patient’s disease state and enable multiple parametric deep data sets in genomics, proteomics, and combinatorial analysis. Their capabilities include drug compound testing, enrollment, and collection of patient specimens for model development, defining and monitoring clinically relevant characteristics for each clinical disease category and across patient cohorts. This approach provides more in-depth insight into the heterogeneity of patient characteristics in a disease category and provides information about the stability and utility of the patient-specific model over time.
For more information, please visit www.vyantbio.com; www.ordaos.bio and www.cellariainc.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio Inc.’s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future collaborations and strategic transactions in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc.’s Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio, Inc. disclaims any obligation to update these forward-looking statements.
Vyant Bio Investor Contact
Jennifer K. Zimmons. Ph.D.
Investor Relations
Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com
Phone: +1.917.214.3514
Artificial Intelligence
Globhe and OpenForests Partner to Enhance Environmental Project Monitoring with Global Drone Data Integration
STOCKHOLM, Oct. 1, 2024 /PRNewswire/ — Globhe, a global marketplace for on-demand drone data services, and OpenForests, the innovative force behind the explorer.land platform, are pleased to announce a strategic partnership designed to elevate environmental monitoring and project visualization. This collaboration integrates Globhe’s cutting-edge drone data marketplace into explorer.land, offering organizations a powerful tool to enhance transparency, engagement, and impact in their sustainability projects.
Transforming Environmental Monitoring with On-Demand Drone Data
explorer.land, known for its interactive and transparent project platform, now features high-resolution drone data from Globhe upon request. This integration allows users to experience a more dynamic and detailed view of their environmental projects. By visualizing ‘before and after’ scenarios through drone imagery, organizations can demonstrate the impact of their efforts, making it easier to engage stakeholders and attract support.
“The integration of Globhe’s drone data into explorer.land marks a significant advancement in how environmental projects are monitored and presented,” said Alexander Watson, CEO of OpenForests. “This partnership empowers our users to tell more compelling stories about their work, enhancing both credibility and visibility on a global scale.”
CO₂ Operate’s Gula Gula Food Forest Program
To illustrate the power of this new capability, CO₂ Operate’s Gula Gula Food Forest Program serves as a prime example. Through the integration of drone data into their explorer.land profile, CO₂ Operate has been able to effectively showcase the progress and impact of their carbon offsetting and biodiversity initiatives. This case study highlights how organizations can use this technology to improve the transparency and effectiveness of their sustainability efforts.
“Working with Globhe and OpenForests has provided us with invaluable tools to visualize and communicate the impact of our work,” said Paul Burgers, Founder of CO₂ Operate. “The drone data not only enhances our project’s visibility but also strengthens our commitment to achieving broader sustainability goals.”
Driving Innovation in Environmental Project Management
The partnership between Globhe and OpenForests is set to redefine how environmental and reforestation projects are documented and understood. By combining drone data with explorer.land’s robust visualization tools, organizations can enhance their project profiles, engage a broader audience, and drive greater environmental impact.
Andreas Nordansjö, CMO of Globhe, commented, “Our collaboration with OpenForests represents a transformative step in how environmental projects are managed and executed globally. By integrating our drone data into explorer.land, we’re offering OpenForests clients access to a vast network of professional drone operators in over 147 countries.” He continues “This marketplace approach ensures they receive the best possible price through competitive bidding and guarantees they are working with skilled local professionals who understand the unique challenges of each region”.
CONTACT:
Andreas NordansjöChief Marketing Officer, [email protected]+46(0)736334774
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/globhe/r/globhe-and-openforests-partner-to-enhance-environmental-project-monitoring-with-global-drone-data-in,c4045236
The following files are available for download:
https://news.cision.com/globhe/i/globhe-openforests-pressreleaseimage,c3338830
Globhe-OpenForests-PressReleaseImage
View original content:https://www.prnewswire.co.uk/news-releases/globhe-and-openforests-partner-to-enhance-environmental-project-monitoring-with-global-drone-data-integration-302263954.html
New GenAI-Powered Solution Streamlines the Interview Process to Save Recruiters Time and Reduce Bias
NEW YORK, Oct. 1, 2024 /PRNewswire/ — Symphony Talent, a global leader in talent acquisition solutions, announces the launch of Interview Genius, a groundbreaking feature within its SFX On-Demand Interview (ODI) platform. This AI-powered tool will transform how organizations conduct interviews by automating the creation of structured, fair, and science-backed interview questions tailored to each role.
Interview Genius empowers recruiters by leveraging advanced artificial intelligence and a research-backed Large Language Model (LLM) developed by Industrial-Organizational (I/O) Psychologists and Data Scientists. By inputting details such as job description, industry, and desired competencies, Interview Genius generates relevant and consistent questions so recruiters can save time while ensuring every candidate is evaluated without bias.
“The power of AI to transform talent acquisition cannot be overstated,” added Kermit Randa, CEO of Symphony Talent. “With Interview Genius, we’re offering our clients an intelligent, science-backed solution that streamlines the hiring process while maintaining the highest standards of fairness and objectivity. This is how technology can elevate the human element in recruiting, and we’re thrilled to be adding it to our suite of full-funnel SFX solutions.”
Designed specifically for recruiters, Interview Genius delivers:
Time-Savings: Reduce manual work with AI-generated interview questions based on role specifics so recruiters can focus more on building relationships.Fairness and Consistency: Ensure that all candidates are asked the same questions, promoting an equitable and unbiased hiring process.Streamlined Processes: Optimize workflows and ensure data consistency across systems by integrating with Symphony Talent’s SFX CRM.”Interview Genius represents the future of structured interviewing,” said Perry Steinberg, Chief Product Officer at Symphony Talent. “Our goal was to develop a feature that not only saves time but also ensures every candidate is evaluated fairly and consistently, delivering a better experience for both recruiters and applicants.”
Interview Genius is a standard feature within Symphony Talent’s SFX On-Demand Interview platform. This ensures all clients have access to its AI-powered capabilities as part of their ODI experience and guarantees an immediate benefit from tailored, consistent and fair interviews without additional setup or complexity.
About Symphony TalentSymphony Talent delivers innovative, award-winning talent acquisition solutions that empower clients worldwide to expertly advance talent and teams. Our comprehensive suite of full-funnel solutions, expert brand services, and data analytics tools help clients execute and optimize hiring strategies, ensuring differentiated candidate experiences and improved business outcomes at every stage of the talent acquisition funnel, from attraction to hire. Visit symphonytalent.com to learn more.
Logo – https://mma.prnewswire.com/media/2287879/ST_Logo_Single_Line_Full_Color__12_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/symphony-talent-unveils-interview-genius-302262910.html
Expanded European presence aims to meet increasing global demand from the life science industry.
RED BANK, N.J., Oct. 1, 2024 /PRNewswire/ — Astrix, the leader in delivering innovative strategies and solutions to the life science community through its market-leading strategic consulting and technology services, is proud to announce its continued momentum and expansion in Europe, fueled by growing demand for its offerings. In addition to a continuously expanding global team of life science professionals across its U.S. offices and European headquarters in Ireland, the company is also planning to establish new locations in Europe in the near future to accommodate its rapid growth and new customers in the region since formally launching last year.
“We knew, when Astrix launched in Europe last year, that there was a demand for our highly-specialized strategic and technical services. It turns out the need is even greater than we could have imagined and we are excited to extend our support, global perspective, and the unique approach we bring as a company to meet the need for even more clients in the European market,” said Dale Curtis, CEO of Astrix.
Astrix maintains a dedicated workforce of technologists, former scientists, and domain experts from the life science community, with 90% holding advanced science degrees. This deep expertise enables Astrix to deliver unmatched expertise and support to its pharmaceutical, life science, and biotech customers worldwide with its strategic and technical initiatives in and around the laboratory. As the industry faces new challenges in a highly-regulated and rapidly-evolving environment, Astrix assists its global clients by offering:
Expert guidance on emerging trends helping organizations get ahead and succeed in digital transformation and AI readiness with tailored, innovative strategies.A technology and platform agnostic approach, customizing every aspect to fit the client’s unique challenges, rather than one-size-fits-all.Unified team collaboration from the very beginning of planning through to execution. Unlike other consulting firms with fragmented and siloed teams, Astrix offers its customers a thoughtfully-assembled dedicated group of experts taking a more holistic approach to meeting its business goals.”We believe deeply in the importance of having a strong local presence – understanding the people, the markets, and the regulations in the regions we support. This commitment to being on the ground, close to our clients, is a big part of what sets us apart and what we will continue to prioritize as we expand across Europe,” said Michael Gannon, Director of Astrix Europe.
Between now and the end of the year, the Astrix team will be attending or presenting at events across Europe, including:
– The Lab of the Future Congress, October 1-2 in Amsterdam- BioTechX, October 9-10 in Basel, Switzerland
For more information about Astrix Europe, please visit https://astrixinc.com/astrix-europe/.
About Astrix
Astrix is the unrivaled market leader in creating & delivering innovative strategies and solutions to the life science community. Through world-class people, processes, and technology, Astrix works with clients to fundamentally improve business, scientific outcomes, and the quality of life everywhere. Founded by scientists to solve the unique challenges of the life science community, Astrix offers a growing array of strategic and technical services designed to deliver value to clients across their organizations.
Logo – https://mma.prnewswire.com/media/2520183/astrix_logo_transparent_1920__1_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/astrix-accelerates-global-expansion-with-enhanced-presence-in-europe-302263860.html
-
Artificial Intelligence4 days agoCluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review
-
Uncategorized4 days agoMC Digital Realty wins Frost & Sullivan’s 2024 Japan Data Center Services Company of the Year Award
-
Artificial Intelligence4 days agoHyperlink InfoSystem Takes the Spotlight as a Top AI Development Company in USA 2024
-
Uncategorized4 days ago
Prime Minister concludes successful visit from President of France to Canada
-
Artificial Intelligence4 days agoHow AIoT shapes the future of mobility: Hikvision at ITS World Congress 2024
-
Artificial Intelligence4 days agoWondershare to Showcase Enterprise Solution Excellence at GITEX GLOBAL 2024
-
Artificial Intelligence4 days agoAnti-Drone Market worth $7.05 billion by 2029 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence7 days agoJames Cameron, Academy Award-Winning Filmmaker, Joins Stability AI Board of Directors
